Roche bags EU nod for subcutaneous MabThera shot
The European Commission has approved a subcutaneous formulation of Roche’s MabThera for chronic lymphocytic leukaemia, saving time and easing the treatment burden compared with drug’s intravenous form, says the drugmaker.
Read More
